$OPNT News
Last published 3y ago
- 3y agoOPNTApproval of Opvee, Nda #217470 (Type 3 - New Dosage Form)FDA Approved DrugsApproval Date: 05/22/2023; Drug Name: Opvee, Nda #217470; Active Ingredients: NALMEFENE; Company: Opiant Pharmaceuticals Inc; Submission Status: Approval; Submission Classification: Type 3 - New Dosage Form; Application Number: 217470
- 3y agoOPNTApproval of Opvee (nalmefene), Nda #217470 (Type 3 - New Dosage Form)FDA Approved DrugsApproval Date: 05/22/2023; Drug Name: Opvee (nalmefene), Nda #217470; Active Ingredients: OPVEE (nalmefene); Company: Opiant Pharmaceuticals Inc; Submission Status: Approval; Submission Classification: Type 3 - New Dosage Form; Application Number: 217470
- 3y agoOPNTFDA Approves Prescription Nasal Spray to Reverse Opioid OverdoseFDA Press ReleasesToday, the U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. This is the first FDA approval of nalmefene hydrochloride nasal spray for health care and community use. “The agency continues to advance the FDA Overdose Prevention F ...
- 3y agoOPNTSCORFEYEDeepwatch Names Mel Wesley as Chief Financial OfficerBusiness WireSuccessful finance and cybersecurity industry veteran to support rapid growth Deepwatch, the leader in advanced managed detection and response (MDR) security, announced today the appointment of Mel Wesley as Chief
- 3y agoOPNTOpiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCGlobeNewswireCFIUS clearance represents the final required regulatory approval to complete the proposed mergerCompletion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition
- 3y agoOPNTOpiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLCGlobeNewswireSANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as
- 3y agoOPNTOpiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid OverdoseGlobeNewswireFDA sets PDUFA date of May 22, 2023 SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT) today announced that the U.S. Food and Drug Administration (FDA) has
- 3y agoINVVYOPNTIndivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth OutlookPR Newswire- Peak Annual Net Revenue Potential for SUBLOCADE® Increased to >$1.5 Billion - Attractive and Scalable Business Outlined – Expects Strong Net Revenue Growth and Operating Margin Expansion Over the Medium-term -
- 3y agoOPNTOpiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid OverdoseGlobeNewswireSANTA MONICA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT) today announced it has completed submission of its rolling New Drug Application (NDA) to the U.S. Food and
- 3y agoOPNTOPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant PharmaceuticalsGlobeNewswireMONSEY, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) ("Opiant") acted in the best interests of
- 3y agoOPNTOpiant Pharmaceuticals Announces Third Quarter 2022 Financial ResultsGlobeNewswireSANTA MONICA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today
- 3y agoOPNTIndivior PLC to Acquire Opiant PharmaceuticalsGlobeNewswireIndivior to acquire Opiant Pharmaceuticals for total consideration of $28.00 per share comprising of an upfront cash payment of $20.00 per share at closing plus contingent value rights (CVRs) worth up to $8.00 per share
- 3y agoINVVYOPNTIndivior To Acquire Opiant PharmaceuticalsPR NewswireAcquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristics Well-Suited to
- 4y agoOPNTOpiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022GlobeNewswireSANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant" or "Company") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose,
- 4y agoOPNTOpiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis SyndromeGlobeNewswireSANTA MONICA, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ:OPNT) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Opiant's pipeline candidate OPN
- 4y agoMNMDOPNTMindMed Strengthens Board with Appointment of Two New Independent DirectorsPR NewswireNEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr.
- 4y agoOPNTOpiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate UpdateGlobeNewswireSANTA MONICA, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the thre
- 4y agoOPNTOpiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal NalmefeneGlobeNewswireSANTA MONICA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded an additional approximately $2.1 millio
- 4y agoOPNTOpiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid OverdoseGlobeNewswireSANTA MONICA, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ:OPNT) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 16/461,354,
- 4y agoOPNTOpiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022GlobeNewswireSANTA MONICA, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant" or "Company") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report
- 4y agoOPNTOpiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSANTA MONICA, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant" or "Company") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation
- 4y agoOPNTOpiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal NalmefeneGlobeNewswireSANTA MONICA, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ:OPNT) today announced a capacity investment agreement with Aptar Pharma (Aptar), a leading provider of drug delivery systems, to expand production o
- 4y agoOPNTOpiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid OverdoseGlobeNewswireCompany expects to complete submission of the NDA using the 505(b)(2) pathway, as previously agreed upon with the FDA, in the second half of 2022 SANTA MONICA, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDA
- 4y agoOPNTOpiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDTGlobeNewswireSANTA MONICA, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), announced today that to protect the health and safety of its shareholders, employees, and communities amidst a rise locally in COVID-19, Opia
- 4y agoOPNTOpiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireSANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three
- 4y agoOPNTOpiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022GlobeNewswireSANTA MONICA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the firs
- 4y agoOPNTOpiant Pharmaceuticals Issues Statement in Response to Fake Press ReleasePR NewswireSANTA MONICA, Calif., April 29, 2022 /PRNewswire/ -- Opiant Pharmaceuticals (NASDAQ:OPNT) was the subject of a fake news release issued on Friday, April 29, 2022, that falsely stated Opiant announced a partnership with Hikma Pharmaceuticals, PLC. O
- 4y agoOPNTOpiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal NaloxoneGlobeNewswireStudy compared OPNT003, nasal nalmefene, with 4 mg nasal naloxone hydrochloride in reversing the respiratory depression produced by remifentanil, a synthetic opioid OPNT003 met the primary endpoint of non-inferiority, which was designed to assess wheth
- 4y agoOPNTOpiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswireSANTA MONICA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the thr
- 4y agoOPNTOpiant Pharmaceuticals to Participate in 32nd Oppenheimer Healthcare ConferenceGlobeNewswireSANTA MONICA, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Chief Executive Officer,
- 4y agoOPNTOpiant Pharmaceuticals to Report Fourth Quarter 2021 Financial Results and Host Conference Call and Webcast on March 15, 2022GlobeNewswireSANTA MONICA, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report fourth quarter 20
- 4y agoOPNTOpiant Pharmaceuticals Announces Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study for OPNT003, Nasal NalmefeneGlobeNewswireSANTA MONICA, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT) today announced positive topline results from a multi-dose pharmacokinetic ("PK") study for OPNT003, nasal nalmefene, an investigational trea
- 4y agoOPNTOpiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development ProgramGlobeNewswireSANTA MONICA, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority ("BARDA") for an additional
- 4y agoOPNTOpiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use DisorderGlobeNewswirePhase 2 trial to evaluate reduction in heavy drinking as measured by a change in the World Health Organization drinking risk levels1 Trial is informed by results from Phase 1 studies that showed pharmacokinetic properties of OPNT002 well suited for ��
- 4y agoOPNTOpiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSANTA MONICA, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant" or "Company") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation
- 4y agoBYSICPRXOPNTPALICARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics CorporationPR NewswireSHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced to
- 4y agoOPNTOpiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSANTA MONICA, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant" or "Company") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation
- 5y agoOPNTOpiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireSANTA MONICA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the thre
- 5y agoOPNTOpiant Pharmaceuticals to present at Jefferies Virtual London Healthcare ConferenceGlobeNewswireSANTA MONICA, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a company advancing medicines to better treat addictions and drug overdose, today announced that members of the company's senior management
- 5y agoOPNTOpiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid OverdoseGlobeNewswireFast Track Designation further underscores the potential for OPNT003 to represent a major advance in the treatment of opioid overdose as opioid overdose deaths surge1 This designation enables early and frequent communication with the FDA, in addition
- 5y agoOPNTOpiant Announces Publication of Manuscript Treatment of Overdose in the Synthetic Opioid Era in Peer-Reviewed Journal Pharmacology & TherapeuticsGlobeNewswireSANTA MONICA, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a company advancing medicines to better treat addictions and drug overdose, today announced the publication of a manuscript entitled "Treatme
- 5y agoOPNTOpiant Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021GlobeNewswireSANTA MONICA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report third quarter 2021
- 5y agoOPNTOpiant Pharmaceuticals to Participate in September Investor ConferencesGlobeNewswireSANTA MONICA, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT) today announced that members of the company's senior management team will participate in the following virtual investor conferences: H.
- 5y agoOPNTOpiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireSANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the thre
- 5y agoOPNTOpiant Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021GlobeNewswireSANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial resu
- 5y agoOPNTOpiant Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSANTA MONICA, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced, as required by Nasdaq Stock
- 5y agoOPNTOpiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial OfficerGlobeNewswireMr. Ruth led the highly successful launch and commercialization of the first FDA-approved nasal naloxone spray to treat opioid overdose He joins Opiant at a time when the Company is developing and moving towards potential commercialization of OPNT003,
- 5y agoCLOVOPNTRNWKVRAY+1Thinking about buying stock in Opiant Pharmaceuticals, RealNetworks, Vaxart, Clover Health, or Viewray?PR NewswireNEW YORK, July 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OPNT, RNWK, VXRT, CLOV, and VRAY. T
- 5y agoOPNTOpiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid OverdoseGlobeNewswireData demonstrate rapid absorption and higher plasma concentrations versus an intramuscular injection (p<0.0001) Results confirm findings of initial pilot PK study SANTA MONICA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, I
- 5y agoOPNTOpiant Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare ConferenceGlobeNewswireSANTA MONICA, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, D